← Back to Screener
Iovance Biotherapeutics, Inc. Common Stock (IOVA)
Price$3.80
Favorite Metrics
Price vs S&P 500 (26W)64.30%
Price vs S&P 500 (4W)-4.50%
Market Capitalization$1.57B
All Metrics
Book Value / Share (Quarterly)$1.70
P/TBV (Annual)2.58x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.82
Price vs S&P 500 (YTD)37.28%
Gross Margin (TTM)28.66%
Net Profit Margin (TTM)-148.38%
EPS (TTM)$-1.12
10-Day Avg Trading Volume16.76M
EPS Excl Extra (TTM)$-1.12
EPS (Annual)$-1.09
ROI (Annual)-55.89%
Gross Margin (Annual)34.28%
Cash / Share (Quarterly)$0.72
Revenue Growth QoQ (YoY)17.74%
ROA (Last FY)-42.82%
Revenue Growth TTM (YoY)60.60%
EBITD / Share (TTM)$-1.06
ROE (5Y Avg)-63.72%
Operating Margin (TTM)-153.08%
Cash Flow / Share (Annual)$-0.82
P/B Ratio2.25x
P/B Ratio (Quarterly)1.55x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)5.36x
Net Interest Coverage (TTM)-8.26x
ROA (TTM)-42.36%
EPS Incl Extra (Annual)$-1.09
Current Ratio (Annual)3.20x
Quick Ratio (Quarterly)2.74x
3-Month Avg Trading Volume14.64M
52-Week Price Return12.02%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.02
P/S Ratio (Annual)5.97x
Asset Turnover (Annual)0.29x
52-Week High$5.63
EPS Excl Extra (Annual)$-1.09
CapEx CAGR (5Y)-6.28%
Tangible BV CAGR (5Y)27.99%
26-Week Price Return68.28%
Quick Ratio (Annual)2.74x
13-Week Price Return59.17%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.20x
Enterprise Value$1,411.615
Asset Turnover (TTM)0.29x
Book Value / Share Growth (5Y)-17.62%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-149.16%
Cash / Share (Annual)$0.72
3-Month Return Std Dev104.85%
Net Income / Employee (TTM)$-0
ROE (Last FY)-55.97%
Net Interest Coverage (Annual)-0.64x
EPS Basic Excl Extra (Annual)$-1.09
Receivables Turnover (TTM)3.47x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.12
ROI (TTM)-54.47%
P/S Ratio (TTM)5.97x
Revenue / Share (Annual)$0.74
Tangible BV / Share (Annual)$1.02
Price vs S&P 500 (52W)-17.81%
Year-to-Date Return39.93%
5-Day Price Return-4.74%
EPS Normalized (Annual)$-1.09
ROA (5Y Avg)-48.85%
Net Profit Margin (Annual)-148.38%
Month-to-Date Return8.83%
Cash Flow / Share (TTM)$-1.96
EBITD / Share (Annual)$-1.03
Operating Margin (Annual)-153.08%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-63.61%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.12
P/TBV (Quarterly)2.58x
P/B Ratio (Annual)1.55x
Inventory Turnover (TTM)3.64x
Pretax Margin (TTM)-149.16%
Book Value / Share (Annual)$1.70
Price vs S&P 500 (13W)58.48%
Beta0.77x
Revenue / Share (TTM)$0.65
ROE (TTM)-54.54%
52-Week Low$1.64
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.78
3.78
3.94
3.94
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IOVAIovance Biotherapeutics, Inc. Common Stock | 5.97x | 60.60% | 28.66% | — | $3.80 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Iovance Biotherapeutics is a biopharmaceutical company developing autologous TIL (tumor-infiltrating lymphocyte) cell therapies for solid tumors. The company's personalized approach harnesses patients' own immune cells to target and destroy cancer cells. Iovance is advancing toward U.S. regulatory approval and commercialization of what could be the first autologous T-cell therapy for solid tumor cancers.